LLY's MAB targets viral proteins and trial for critical patients has been stopped due to no perceived / observed benefit. This will happen to every MAB targeting viral spike proteins eventually, as mutations reduce binding site affinity. Several contenders, aware of this, have attempted to circumvent by having a cocktail of two or more MABs targeting different viral elements, but all that does is stretch out effectiveness a small bit further.. one mutation could render several MABs useless / unable to bind.

The longer it takes for these MABs to hit the market, the more likely they'll arrive to find already mutated SARS-Cov-2, and be DOA.

https://www.msn.com/en-us/money/companies/u-s...li=BBnbfcN